Q-omics provides the consensus-scored MTUS2 profile across patient tissues and cancer cell-line models. MTUS2 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, MTUS2 is differentially expressed in 9, with the highest sampling consensus in KICH. Additionally, MTUS2 protein abundance shows 15,620 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UVM, KICH, and GBM as cancer lineages where MTUS2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MTUS2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MTUS2 survival associations across molecular data types. MTUS2 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (10) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MTUS2 RNA expression–survival associations across cancer types. High MTUS2 expression shows unfavorable associations in UVM, UCEC and KIRP, but favorable associations in UCS, PAAD and LGG. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for MTUS2 RNA expression.
This table summarizes MTUS2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 2. The strongest signals are observed in KICH for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for MTUS2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MTUS2 shows lower tumor expression in UCEC, COAD, STAD, THCA and LIHC and higher tumor expression in KICH. The KICH box plot shows higher MTUS2 RNA expression in tumor versus normal tissue (log2 FC = +1.447, t-test p < 0.001).
This table shows molecular features associated with MTUS2 in patient tissues and cancer cell lines. In patient samples, MTUS2 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, MTUS2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in CNS and BLOOD_Leukemia.
